# How a Specific Peptide Boosts the Immune System Against Cancer

> This patent describes a specific peptide sequence, KESDGFHRF, combined with immune-boosting substances and a safe delivery method, for use in treating cancer through immunotherapy.

- **Patent:** US 11542303
- **Original title:** Peptides and combination thereof for use in the immunotherapy against cancers
- **Owner:** Immatics Biotechnologies
- **Granted:** 2023
- **Status:** Active
- **Times cited:** 1
- **Field:** biotech, pharmaceutical, immunotherapy

## What it does

This patent claims a specific recipe for a cancer treatment. It involves a particular protein fragment, called a peptide, with the exact amino acid sequence KESDGFHRF (Claim 1). This peptide is combined with an 'adjuvant,' which is a substance that helps make the immune response stronger. The patent lists several possible adjuvants, including imiquimod, GM-CSF, and various interleukins like IL-2, IL-7, IL-12, IL-15, and IL-21 (Claim 2). All these ingredients are mixed into a 'pharmaceutically acceptable carrier,' which is a safe way to deliver the medicine to a patient. For example, a composition could include the KESDGFHRF peptide, IL-2 as the adjuvant (Claim 3), and a buffer for stability (Claim 8), all within a safe liquid carrier for injection.

## What it does NOT cover

- Does not cover cancer immunotherapies that use different peptide sequences than KESDGFHRF.
- Does not cover the peptide KESDGFHRF when administered without an adjuvant.
- Does not cover the peptide KESDGFHRF without a pharmaceutically acceptable carrier.
- Does not cover using only the listed adjuvants without the specific KESDGFHRF peptide.
- Does not cover non-immunotherapy treatments for cancer, such as chemotherapy alone.

## The clever bit

The novelty lies in identifying and claiming a very specific nine-amino-acid peptide, KESDGFHRF, as a key component for stimulating an immune response against tumors. The patent then combines this specific peptide with known immune-boosting adjuvants and delivery methods, creating a precise formulation for immunotherapy.

## Real-world examples

1. Experimental cancer vaccines
2. T-cell stimulating therapies
3. Immunotherapy drug candidates

## Why it matters

Cancer immunotherapy aims to train a patient's own immune system to recognize and destroy cancer cells. This patent contributes to that field by identifying a specific peptide that can potentially act as a target for the immune system. By combining this peptide with adjuvants, the goal is to create a stronger, more focused anti-tumor immune response, offering a new approach to fight various cancers.

## Frequently asked questions

### What does How a Specific Peptide Boosts the Immune System Against Cancer cover?

This patent describes a specific peptide sequence, KESDGFHRF, combined with immune-boosting substances and a safe delivery method, for use in treating cancer through immunotherapy.

### Who owns patent US 11542303?

Immatics Biotechnologies owns this patent, granted in 2023.

### When does this patent expire?

This patent is expected to expire on June 25, 2041, when the invention enters the public domain.

### What is patent US 11542303 cited by?

This patent has been cited by 1 later patents that build on its ideas.

### What problem does this patent solve?

Cancer immunotherapy aims to train a patient's own immune system to recognize and destroy cancer cells. This patent contributes to that field by identifying a specific peptide that can potentially act as a target for the immune system. By combining this peptide with adjuvants, the goal is to create a stronger, more focused anti-tumor immune response, offering a new approach to fight various cancers.

### What does this patent NOT cover?

Does not cover cancer immunotherapies that use different peptide sequences than KESDGFHRF.

**Full plain-English explainer:** https://patentbrief.org/patent/us/11542303/peptides-and-combination-thereof-for-use-in-the-immunotherapy-against-cancers

**Original patent:** https://patents.google.com/patent/US11542303

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._